X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
1. 7-(4-(4-(1-benzothiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1h)-one
2. Rexulti
1. 913611-97-9
2. Opc-34712
3. Rexulti
4. 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1h)-one
5. Opc 34712
6. 2j3ybm1k8c
7. 7-(4-(4-(1-benzothiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1h)-one
8. 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1h-quinolin-2-one
9. Brexpiprazole [usan]
10. Unii-2j3ybm1k8c
11. Brexpiprazole [usan:inn]
12. Rxulti
13. Rexulti (tn)
14. Brexpiprazole.2h2o
15. Brexpiprazole-[d8]
16. Brexpiprazole [mi]
17. Brexpiprazole [inn]
18. Brexpiprazole [jan]
19. Brexpiprazole(opc34712)
20. Brexpiprazole; Opc-34712
21. Brexpiprazole [who-dd]
22. Gtpl7672
23. Schembl1037592
24. Brexpiprazole (jan/usan/inn)
25. Chembl2105760
26. Schembl14772509
27. Amy6914
28. Dtxsid40238527
29. Chebi:134716
30. Hms3885p12
31. Brexpiprazole [orange Book]
32. Bcp10218
33. Bcp24077
34. Ex-a2639
35. Opc34712
36. Mfcd27987920
37. S4639
38. Zinc84758479
39. Akos025291100
40. Akos037515802
41. Ccg-269055
42. Db09128
43. Sb16735
44. Ncgc00378574-01
45. Ncgc00378574-02
46. Ac-30404
47. As-56467
48. Da-35913
49. Hy-15780
50. Ft-0712292
51. A13527
52. D10309
53. Q2924764
54. 2(1h)-quinolinone, 7-(4-(4-benzo(b)thien-4-yl-1-piperazinyl)butoxy)-
55. 7-[4-(4-benzo[b]thien-4-yl-1-piperazinyl)butoxy]- 2(1h)-quinolinone
56. 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1h-quinolin-2-one
57. 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one
58. 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1h-quinolin-2-one
| Molecular Weight | 433.6 g/mol |
|---|---|
| Molecular Formula | C25H27N3O2S |
| XLogP3 | 4.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 7 |
| Exact Mass | 433.18239829 g/mol |
| Monoisotopic Mass | 433.18239829 g/mol |
| Topological Polar Surface Area | 73 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 636 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
As an adjunctive treatment of major depressive disorder (MDD) and for treatment of schizophrenia.
FDA Label
Treatment of schizophrenia.
Dopamine Agonists
Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)
Serotonin Agents
Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons. (See all compounds classified as Serotonin Agents.)
N05AX16
N - Nervous system
N05 - Psycholeptics
N05A - Antipsychotics
N05AX - Other antipsychotics
N05AX16 - Brexpiprazole
Absorption
Brexpiprazole reaches peak plasma concentration within 4 hours of administration, and steady state occurs within 10-12 days of dosing. Oral bioavailability is 95%, and can be administered with or without food.
Route of Elimination
Approximately 25% urinary and 46% fecal excretion. <1% and ~14% of the unchanged drug was recovered in the urine and feces, respectively.
Volume of Distribution
Intravenous volume of distribution is 1.56L/kg.
Clearance
19.8mL/h/kg
Metabolized mainly by CYP3A4 and CYP2D6 enzymes into its major metabolite, DM-3411. DM-3411 is not considered to contribute any therapeutic effect.
Brexpiprazole and its major metabolite, DM-3411 have half lives of 91 and 96 hours respectively.
Although the mechanism of action of brexpiprazole in the treatment of MDD and schizophrenia is unclear, the efficacy of brexpiprazole may be attributed to partial agonist activity at serotonin 1A and dopamine D2 receptors, and antagonist activity at serotonin 2A receptors.
Market Place
